SANA צמיחת רווחי EPS רבעונית Sana Biotechnology, Inc.
Sana Biotechnology operates its own sterile manufacturing facility in California to produce gene products. After analyzing the quarterly EPS growth rate on GURU.Markets, we find that 141.50 forms the current metric value. The company is developing breakthrough hypoimmune stem cells for cancer treatment. The financial model relies on partnership payments and the future sale of organ restoration technologies.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_SANA_-_Sana-Biotechnology_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "sana.com (SANA): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 15.11.2026 | 👁️GURU.Markets👁️")
Sana Biotechnology (SANA) - פילוחי מדדים ודוחות פיננסיים
This metric evaluates operational efficiency through the rate of change in earnings per share. It determines the business's financial margin of safety amid market contraction and declining demand. For Sana Biotechnology (SANA), this calculation is critical due to risks involving ingredient supply chain disruptions and patent disputes. Geopolitical barriers directly impact the profitability of drug development. Analyze these dependencies through quarterly EPS dynamics.
